Study links dietary intake of isoflavones with elevated risk of advanced prostate cancer

NewsGuard 100/100 Score

Dietary intake of isoflavones was linked with an elevated risk of advanced prostate cancer in a recent International Journal of Cancer study. No statistically significant associations were observed between the intake of isoflavones and non-advanced prostate cancer.

Isoflavones are a type of phytoestrogen, a family of estrogen-like compounds found in plants, and are found in soybeans, kudzu root, and American groundnuts.

During a median follow up of 11.5 years, 2598 cases of prostate cancer (including 287 advanced cases) were identified among 27,004 men in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Dietary intake was assessed with a food frequency questionnaire.

"Prostate cancer is a major cancer in Western countries and its incidence rate has been remarkably increasing in Asian countries during the last several decades," said senior author Dr. Jianjun Zhang, of the Indiana University Fairbanks School of Public Health. "Our study offers novel evidence that dietary intake of isoflavones has different effects on advanced and non-advanced prostate cancer. This observation is important for understanding the etiology and prevention of prostate cancer but needs to be confirmed in more epidemiologic studies among populations with diverse dietary habits."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer